Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$155.29 USD
+0.46 (0.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $155.34 +0.05 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$155.29 USD
+0.46 (0.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $155.34 +0.05 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum D VGM
Zacks News
Ecolab's New Pest Elimination Service to Ensure Food Safety
by Zacks Equity Research
Ecolab's (ECL) introduces Rodent Ceiling Service, which can help reduce the risk to food safety and public health.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Surmodics (SRDX), thanks to solid prospects.
Conformis Next-Generation Identity PS Knee System Gets FDA Nod
by Zacks Equity Research
Conformis' (CFMS) latest iTotal Identity PS Knee System clears FDA hurdle, paving the way for providing better patient-specific pre-operative surgical plans.
3 Best GARP Stocks to Beat Pandemic-Led Market Inefficiency
by Urmimala Biswas
The unprecedented global health crisis is providing a psychological shock to the investment world.
NextGen Virtual Visits Supports Women Health During COVID-19
by Zacks Equity Research
Capital Women's Care is set to expand NextGen's (NXGN) women's healthcare services during the coronavirus emergency.
Patterson Companies (PDCO) Q4 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results reflect dismal performance by Dental and Animal Health segments.
Masimo (MASI) Boosts Product Portfolio with New Solution
by Zacks Equity Research
Masimo (MASI) unveils Masimo Sleep to help consumers better understand their quality of sleep.
Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes
by Zacks Equity Research
Amedisys (AMED) benefits from the recent acquisitions of hospice care providers, Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice.
Medtronic's Evolut TAVI Gets CE Mark for Low-Risk Patients
by Zacks Equity Research
Medtronic's (MDT) Evolut system shows a lower rate of the composite of all-cause death or disabling stroke with TAVI at 30 days.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect solid performance at Dental segment.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.
Zimmer Biomet Adds New Features to mymobility with Apple Watch
by Zacks Equity Research
Zimmer Biomet (ZBH) expands mymobility digital platform by leveraging Apple's ecosystem to enhance patients' post-operative care.
Allscripts' (MDRX) Veradigm Partners with PAN Foundation
by Zacks Equity Research
This partnership between Allscripts (MDRX) and PAN Foundation is expected to boost patient outcomes.
Thermo Fisher Grows on Coronavirus Diagnostic Tests Amid Crisis
by Zacks Equity Research
Thermo Fisher (TMO) is optimistic about ramped up production for its COVID-19 diagnostic test to meet growing global demand.
NuVasive Launches Reline 3D for Pediatric Patients Globally
by Zacks Equity Research
Other than Reline 3D, NuVasive's (NUVA) Reline System portfolio has products like Reline Open, Reline MAS, Reline Trauma and Reline Small Stature.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as solid international business.
Medtronic Partners Foxconn to Scale Up Ventilator Production
by Zacks Equity Research
Medtronic (MDT) enters into a partnership with Foxconn with an aim of providing 10,000 PB560 ventilators in the United States over the next year amid the pandemic-led surge in demand for the same.
PerkinElmer's Tie-Up to Boost Health Outcomes in Africa
by Zacks Equity Research
PerkinElmer's (PKI) partnership with ASH likely to boost newborn screening in underserved populations for better health outcomes in Africa.
Henry Schein Dental Software Arm May Rebound Despite Pandemic
by Zacks Equity Research
Henry Schein (HSIC) also seems to be upbeat about its dental technology business, Henry Schein One.
Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis
by Zacks Equity Research
Walgreens' (WBA) tie-ups with Alphabet's life sciences and healthcare segment, Verily on multiple projects related to chronic ailments buoy optimism.
DGX vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. AMED: Which Stock Is the Better Value Option?
Illumina Takes Over BlueBee, Fortifies NGS Data Processing
by Zacks Equity Research
With this acquisition, the cloud capability of BlueBee's platform will help Illumina (ILMN) to lower the cost of storing, sharing and managing the company's huge volumes of genomic data.
Tandem Diabetes Gets Expanded Indication for Insulin Pump
by Zacks Equity Research
Tandem Diabetes (TNDM) receives clearance for expanded indication for pediatric use of t:slim X2 insulin pump with Control-IQ, paving the way for simpler diabetes management in younger patient pool.
Accuray's New CyberKnife S7 System to Boost Patient Care
by Zacks Equity Research
Accuray's (ARAY) newly launched CyberKnife S7 System will enable clinicians to provide best possible care to their patients through new capabilities.
Myriad Genetics' Prolaris Receives Favorable Coverage Policies
by Zacks Equity Research
Myriad Genetics (MYGN) paves the way for bringing more prostate cancer patients under the purview of Prolaris testing through their health plan.